• Texas Pradaxa Lawyer: Get Your Texas Pradaxa  Lawyer Texas Pradaxa Lawyer  Network has Texas Pradaxa  lawyers ready to help you if you have been injured by Pradaxa extensive bleeding in: Dallas, Houston, Abilene, Amarillo, Austin, Arlington,...
  • Xarelto Lawsuit Helpline | Xarelto Lawyers: Xarelto Lawsuit Helpline Get An Xarelto Extensive Bleeding Lawyer If you or a loved one took Xarelto for prevention of blood clots and pulmonary embolisms and this resulted in severe injury or death  contact  Xarelto L...
  • Texas Blood Clot Filter Lawyer Files IVC Filter Lawsuit: The IVC Filter Helpline keeps you updated on all the latest news regarding IVC Filter lawsuits and all lawsuits pertaining to products and drugs that claim they will help people avoid blood clots and the resulting stroke...

Breaking Pradaxa News, Pradaxa Lawyers Filing Lawsuits for Pradaxa

Written by Xarelto Helpline on . Posted in Florida Xarelto Lawyer, Texas Xareleto Lawyer, Xarelto News

EMA Recommends Patient, Prescriber Information For Pradaxa Be Updated Pradaxa Helpline Reports, Extensive Bleeding from pradaxa

    May 25, 2012, 5:17 a.m. ET

EMA Recommends Patient, Prescriber Information For Pradaxa Be Updated Pradaxa Helpline geriatric Social Worker is extremely concerned about the elderly on Pradaxa

LONDON (Dow Jones)–The European Medicines Agency, or EMA, Friday recommended updating the product information for the blood thinner Pradaxa, to give clearer guidance to doctors and patients on how to reduce and manage the risk of bleeding associated with the anticoagulant medicine.

MAIN FACTS:

-Bleeding is a well-known complication of all anticoagulant medicines and Pradaxa has therefore been kept under close review by the Agency's Committee for Medicinal Products for Human Use, or CHMP, since its initial authorization.

-Committee's recommendation to update the product information follows the assessment of all available data, including from post-marketing surveillance, on Pradaxa and the risk of serious or fatal bleedings.

-Committee found that the frequency of occurrence of fatal bleedings with Pradaxa seen in post-marketing data was significantly lower than what was observed in the clinical trials that supported the authorization of the medicine, but considered that this issue should nonetheless be kept under close surveillance.

-CHMP concluded that the benefits of Pradaxa continue to outweigh its risks and that it remains an important alternative to other blood-thinning agents.

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,